The CAT Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population from the 769-P renal cell carcinoma line, targeting the CAT gene encoding catalase. This heterogeneous pool of gene-disrupted cells enables loss-of-function studies without single-cell cloning, providing a robust model to investigate catalase-dependent mechanisms in a disease-relevant context.
The parental 769-P line is derived from a primary clear cell adenocarcinoma and serves as a well-established model for clear cell renal cell carcinoma. It retains characteristic genetic and metabolic features, making it suitable for studying redox biology and catalase function in kidney cancer.
Catalase is a key antioxidant enzyme that decomposes hydrogen peroxide (H?O?) into water and oxygen, protecting cells from oxidative damage. Its expression is regulated by transcription factors Nrf2, FoxO3, and NF-??B in response to oxidative stress and pro-inflammatory signals like TNF-alpha. Catalase interacts with superoxide dismutase and the peroxisomal import receptor PEX5, and functions within pathways involving glutathione peroxidase, the Nrf2/ARE axis, and FoxO signaling. CAT disruption in 769-P cells leads to H?O? accumulation, heightened oxidative stress, and potential alterations in redox signaling that may impact proliferation, apoptosis, and tumorigenicity.
In 769-P cells, catalase knockout allows dissection of how loss of this antioxidant enzyme influences redox balance, signal transduction, and drug sensitivity. Elevated H?O? may modulate transcription factors Nrf2 and FoxO3, affecting survival and stress-response programs. This model is valuable for exploring oxidative stress contributions to renal cell carcinoma progression and resistance, and for testing therapeutic interventions targeting redox pathways.
Applications include studying oxidative stress responses, redox regulation in cancer, acatalasemia modeling, drug resistance mechanisms, and antioxidant screening. Representative assays encompass catalase activity measurement, Amplex Red H?O? detection, western blotting, DCFDA-based ROS measurement, cell viability under H?O? challenge, colony formation, and comet assay for DNA damage. For further information, please contact Ascent Research.
